Cancer News: Skin
Overall survival in patients with stage 3 melanoma can be significantly increased with ipilimumab as adjuvant therapy.
Adding local peripheral treatments to systemic ipilimumab increased survival in melanoma patients, a retrospective analysis shows.
Novartis's drug combination of Tafinlar and Mekinist increased progression-free survival in lung cancer patients almost up to 10 months, said the company.
In two studies, the PD-1 inhibitors pembrolizumab and nivolumab produced long-duration disease control and long-term survival for some melanoma patients.
Treating advanced melanoma patients with radiation combined with immunotherapy induces better results against melanoma, a research shows.
Advanced melanoma patients lived longer after being treated with pembrolizumab regardless of whether they received previous treatments, a study shows.
Treating patients with previously treated melanoma with immunotherapeutic agent nivolumab Opdivo resulted in an increase in their overall survival, data showed.
Cobimetinib in combination with vemurafenib found to be even more beneficial than cobimetinib alone for melanoma patients, a new study reports.
A new analysis reveals that men with advanced melanoma benefited from a combination treatment of dabrafenib and trametinib.
Scientists were able to see whether a patient with advanced melanoma skin cancer is relapsing by tracking levels of circulating tumor DNA in the blood.
A new study of the association between moles and tumor thickness found that having less moles is associated with reduced risk for thick melanoma.
Melanoma rates have doubled although today we have more tools than even to diagnose melanoma, including genetic and molecular testing.
NICE recommends nivolumab as a treatment for advanced, unresectable or metastatic melanoma.
US regulators approved the combination of nivolumab plus ipilimumab for the treatment of unresectable or metastatic melanoma.
The novel immunotherapy pembrolizumab was approved by the U.S. FDA as first-line treatment for metastatic melanoma.
European regulators have taken a step closer to the treatment of Merkel cell carcinoma, adopting a positive opinion for Orphan Drug designation for avelumab.
U.S. regulators approved Novartis’ drug combination of Tafinlar and Mekinist for the treatment of metastatic melanoma.
Combing cobimetinib and vemurafenib extended the survival rate of previously untreated patients with advanced skin cancer, a new study reports.
According to latest five year survival clinical results, patients with metastatic melanoma were benefited by IMM-101, a pancreatic cancer immunotherapy drug.
U.S. regulators granted breakthrough therapy designation to avelumab for the treatment of patients with metastatic Merkel cell carcinoma.
The U.S FDA approved Cotellic for the treatment of patients with untreated BRAF V600 mutation-positive advanced melanoma.
Patients with stage III melanoma with a high risk of recurrence after surgery can now be treated with Yervoy as the FDA has expanded the use of this melanoma drug.
A viral immunotherapy got approved by EU regulators for the treatment of melanoma patients.
A subset of patients with metastatic melanoma benefited from a combined treatment of immunotherapy and palliative radiation therapy, a new research reveals.
Surgical removal of metastatic melanoma helped patients live more than twice as long as those who receive only medical therapy, according to the results of a new study.
U.S. regulators approved the combination of the immunotherapies nivolumab and ipilimumab for the treatment of patients with melanoma without a BRAF mutation.
Patients of advanced BRAF-mutant melanoma survived longer when treated with a combination of the targeted therapies dabrafenib and trametinib.
Roche’s combination therapy for skin cancer received a positive opinion from the European Commission, bringing closer the approval of the drug for European patients.
Immunotherapy drug ipilimumab benefited only melanoma patients with a specific type of tumor-produced antigens, a new study reveals.
The combination of dabrafenib and trametinib got recommended by European regulators to treat adult melanoma patients with a BRAF V600 mutation.